- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03891056
Metabolic Surgery; Gastric Bypass vs Sleeve Gastrectomy; Efects Over Type 2 DM With Bad Metabolic Control (MSO1CT) (MSO1CT)
METABOLIC SURGERY FOR PATIENTS WITH TYPE 2 DM AND GRADE I OBESITY (BMI 30-35 kg/m2) WITH BAD METABOLIC CONTROL (HbA1c > 7,5%) PROTOCOL
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Hyphotesis Laparoscopic gastric bypass is the elective technique in the face of sleeve gastrectomy to improve or heal type 2 diabetes mellitus in patientes with BMI 30-35 kg/m2.
MAIN AIM:
To compare cure rate through the improvement in glycated hemoglobin and fasting glycaemia after laparoscopic gastric bypass face to sleeve gastrectomy.
SECONDARY AIMS:
To quantify both insulin and oral hypoglycemic agents dose decrease. To measure weight loss and its maintenance during the follow-up in both techniques.
To compare postoperative complications. To compare postoperative pain. To compare follow-up complications.
Matherial and methods. Type of study: Randomized clinical trial double blind with two paralel groups.
RANDOMIZATION. Randomization will be a simple one with Epidat 4.1. A number sequence will be carried out and it will be kept in opaque closed envelopes. The envelope will be opened the operation day and the surgery technique will be decided randomly, according to the randomization sequence. The study will be blinded for patients, who will not know the surgery technique they will go on. Dieticians and Endocrinologists who will follow the patients up after the surgery neither will not know it, so differences in dietary recommendations will not appear with this masking.
Subjects of study The study will rely on patients with Diabetes Mellitus type 2 and grade I obesity with HbA1c higher than 7,5 % (BMI 30-35 kg/m2 and type 2 diabetes with bad glycemic control) detected in Endocrinology and Nutrition Department of Hospital Doctor Peset. Patients will go on bariatric surgery in General and Digestive Surgery Department of the same hospital. Patients who accomplish established inclusion criteria will be recruited until sample size is completed; a minimum 40 patients size is estimated (with a type I error of 5% and a power of 80%) and the will be randomized in two 20 people branches. Investigation will follow The World Medical Association and Declaration of Helsinki guidelines.
Definition of healing and improvement. Healing will be defined when HbA1c and fasting glycaemia levels are inside normal limits without needing oral hypoglycemic agents.
Improvement will be defined when decreasing medication doses for keeping normal fasting glycaemia and level of HbA1c under 6%.
Period of study:
The required one for fulfilling the sample. An inclusion of 40 patients in two years is expected.
Variable-gathering period The patient will be call for attending the external consultation of the Endocrinology and Nutrition Department of Hospital Doctor Peset. Each subject will carry out an initial study with nutritional status assesment, cardiovascular risk factors and comorbidities (hypertension, obstructive sleep apnea, dyslipidemia), as well as discarding secondary causes of obesity. In basal state, 2 days, 3, 6 and 12 months after the surgery, a blood test consisting of biochemical analysis, specific proteins, serum hormones, inmunological markers, full blood count and hemostasis will be made. The patient will carry out dietary intervention and follow-up in each phase of the process.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Nuria Peris Tomás, PhD
- Numero di telefono: 0034 617019132
- Email: nuriapt27@gmail.com
Backup dei contatti dello studio
- Nome: Jose Angel Diez Ares, PhD
- Numero di telefono: 0034 619702452
- Email: jose_angel_diez_ares@hotmail.com
Luoghi di studio
-
-
-
Valencia, Spagna, 46017
- Reclutamento
- Department of General and Digestive Surgery of the Dr. Peset Hospital
-
Contatto:
- Nuria Peris Tomás, PhD
- Numero di telefono: 0034 617019132
- Email: nuriapt27@gmail.com
-
Contatto:
- Jose Angel Diez Ares, PhD
- Numero di telefono: 0034 619702452
- Email: jose_angel_diez_ares@hotmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Both sex patients aged between 18 and 65 years old
- Class I obesity (BMI 30-35 kg/m2) with bad metabolic control (DM-2 with HbA1c > 7,5%) and non-insulin anti-diabetic treatment failure (it is necessary >10 years of known diabetes evolution time, C-peptide≥ 1 ng/ml, no insulin treatment, at least two oral hypoglycemic agents treatment);
- Patients who accomplish the follow-up protocol designed by both Surgery and Endocrinology departments
- Informed consent signed
Exclusion Criteria:
- Patients who do not accomplish the previosly described inclusion criteria; Patient's refusal to take part in the study; Patients with symptomatology of gastroesophageal reflux disease or with upper gastrointestinal series compatible with this desease.
Previous bariatric surgery
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Gastric bypass
Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
|
The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
|
Comparatore attivo: Slevee gastrectomy
Twenty patients will be randomly assigned to perform a sleeve gastrectomy
|
The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of participans with normal glycosylated hemoglobin levels
Lasso di tempo: 1 year after surgery
|
Healing will be defined when HbA1c and fasting glycaemia levels are inside normal limits (Hb1Ac < 6%, FBG<100mg/dl) without needing oral hypoglycemic agents.
|
1 year after surgery
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of participants with partial remission or improvement of diabetes
Lasso di tempo: 1 year after surgery
|
Partial remission: Subdiabetic hyperglycemia (Hb1Ac 6%-6,4%, FBG 100-125mg/dl) in the absence anti diabetic medication. Improvement: statistically significant reduction in Hb1Ac and FBG not meeting criteria for remission or decrease in anti diabetic medication requirement (by one oral agent, or 1/2 reduction in dose) |
1 year after surgery
|
Comparison of weight loss between the two techniques; bypass and sleeve.
Lasso di tempo: 2 years after surgery
|
To measure weight loss and its maintenance during the follow-up in both techniques.
For this, the patients will be weighed in the postoperative period at month, 3, 6 12 months and then annually.
|
2 years after surgery
|
Evaluation of postoperative complications in patients undergoing bypass and slevee with Clavien-Dindo classification.
Lasso di tempo: 1 month after surgery
|
Grade I: any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutritional also included. Grade III: Requiring surgical, endoscopic or radiological intervention. Grade IV: Life-threatening complication requiring IC/ICU management. Grade V: Death of a patient. |
1 month after surgery
|
Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.
Lasso di tempo: 3 days postoperative
|
The postoperative pain of the patients during the first three postoperative days will be evaluated with the visual analogue scale from 0 (no pain) to 10 (unbearable pain).
|
3 days postoperative
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MSO1CT
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su metabolic surgery
-
ARCAGY/ GINECO GROUPReclutamentoCancro ovarico stadio IIIC | Stadio del cancro ovarico IV | Cancro ovarico stadio IIIbFrancia
-
Mayo ClinicTerminatoReflusso gastroesofageo | Ernia, iatale | Sondaggi e questionari | FundoplicatioStati Uniti
-
Fudan UniversitySconosciuto
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... e altri collaboratoriCompletatoCancro ovarico | Cancro della tuba di Falloppio | Cancro della cavità peritonealeSpagna, Francia, Danimarca, Belgio, Germania, Austria, Cina, Italia, Corea, Repubblica di, Norvegia, Svezia, Regno Unito
-
Dr. Faruk SemizIscrizione su invito
-
National Cancer Centre, SingaporeCompletatoMalattie della tiroideSingapore
-
University of TriesteCompletato
-
Kocaeli Derince Education and Research HospitalKocaeli UniversitySconosciutoMiglioramento del recupero dopo l'intervento chirurgico | Chirurgia a cuore apertoTacchino
-
Assiut UniversityNon ancora reclutamentoMalattie esofagee | Complicanza di esofagostomia
-
University of Illinois at ChicagoEthicon Endo-SurgeryRitiratoMalattie del colon e del rettoStati Uniti